Mural Oncology plc
MURADrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Pembrolizumab
Squamous Cell Carcinoma of Head and Neck
Nemvaleukin alfa
Advanced Solid Tumor
ALKS 4230 + pembrolizumab
Advanced Solid Tumors
ALKS 4230
Advanced Solid Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pembrolizumab | Phase 2 | Squamous Cell Carcinoma of Head and Neck | - | - |
Nemvaleukin alfa | Phase 2 | Advanced Solid Tumor | - | - |
ALKS 4230 + pembrolizumab | Phase 2 | Advanced Solid Tumors | - | - |
ALKS 4230 | Phase 2 | Advanced Solid Tumors | - | - |
Frequently asked questions
What is in Mural Oncology plc's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Mural Oncology plc's (MURA) pipeline across Phase 2. Its lead program is Pembrolizumab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Mural Oncology plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Mural Oncology plc (MURA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MURA biotech catalysts?→
Add MURA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Mural Oncology plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.